marcus evans europe conferences

Strategic Drug Repositioning and New Indications Forum

Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs

26-27 September 2013
London, United Kingdom


Why You Should Attend

Strategic Drug Repositioning and New Indications Forum

Drug discovery and development is a time consuming, expensive and risky enterprise

Drug discovery and development is a time consuming, expensive and risky enterprise. In order to accelerate the process with relatively lower costs and reduced risks of failure, pharmaceutical companies have adopted drug repositioning as an alternative approach.

 

Enhancing R&D productivity has captured a growing interest in the pharmaceutical industry. Intense competition for attractive drug candidates has made in-licensing an expensive and sometimes a difficult option for sustaining the pharmaceutical company’s portfolio. Repositioning failed or already marketed drug candidates for alternative disease indications offers a valuable opportunity to alleviate pipeline gaps and increases success rates.

 

How to develop a strategy and business models for drug repositioning? What are the best screening technology platforms? How to overcome IP challenges?  This marcus evans forum will delve into these key issues to ensure companies can overcome their challenges in drug repositioning and new indications.

 

 


Key Topics

  • Explore the latest screening platforms to find new indications
  • Benefit from case studies on successfully repositioned drugs
  • Maximise your knowledge of patent protection
  • Learn about reformulation of existing compounds
  • Ensure success with new indications for already marketed products

  • Why Choose marcus evans?

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.






    Practical Insights From

    Nigel McCracken
    Senior Director, Translational Medicine
    Shire AG

    Graeme Wilkinson
    Associate Director, New Opportunities iMed
    AstraZeneca

    Theo Meert
    Head Neurosciences
    Johnson & Johnson

    Marc Martinell
    Founder & CEO
    Minoryx Therapeutics S.L.

    Raúl Insa
    CEO
    SOM Biotech

    Valery Alakhov
    Vice-President R&D & CSO
    Supratek Pharma Inc

    William Garner
    CEO
    EGB Advisors, LLC

    Sasha Alexandre Akoulitchev
    Director
    Chronos Therapeutics

    Click Here For Full Agenda

    Voice of Our Customers
    Join the Discussion





    Event Contact

    For all enquiries regarding speaking, sponsoring and attending this conference contact:

    Ola Samuelsson


    Regional Marketing Director - Europe & North America
    11 Connaught Place
    London, W2 2ET

    Telephone:
    +44(0)20 3002 3276
    Fax: +44(0)20 3002 3016
    Email: olas@marcusevansuk.com